Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Hohenmölsen

17 clinical trials in Hohenmölsen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hohenmölsen at a glance
17
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

17 trials in Hohenmölsen

Open in trial search

Obesity+1

Recruiting

Phase 3 Extension Trial Evaluating Long‑Term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Obesity

Recruiting

Long‑term Efficacy, Safety and Tolerability of maridebart cafraglutide in Adults with Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Type 2 diabetes mellitus

Recruiting

Randomized trial of elecoglipron with dapagliflozin versus placebo in adults with type 2 diabetes mellitus and impaired renal function

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Glucose tolerance impaired+2

Not yet recruiting

Study of Orforglipron in Overweight Adults at Risk of Developing Obesity‑Related Complications or Class 1 Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Orforglipron hemicalcium
  • Sponsor:Eli Lilly & Co.

Hypercholesterolaemia

Not yet recruiting

Study on the Effects and Safety of MK-0616 for Adults with High Cholesterol

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:MK-0616
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 513 cities in Germany

Clinical research in Hohenmölsen

What the registry says about research in the country

01 Cardiovascular Diseases

Clinical trial research in Hohenmoelsen includes studies in cardiovascular diseases, with a focus on atherosclerotic cardiovascular disease and related efforts to improve heart health outcomes.

  • Evaluating a new treatment approach for people with ASCVD and excess body weight
  • Studying whether therapy can help reduce cardiovascular morbidity and mortality

These trials are designed to assess whether a promising intervention can support better long-term protection against serious cardiovascular events.

02 Nutritional and Metabolic Diseases

The local trial portfolio also covers nutritional and metabolic diseases, especially obesity, overweight, and chronic weight management.

  • Testing a therapy intended to produce meaningful weight loss
  • Assessing whether treatment is effective as part of standard care for adults without type 2 diabetes

These studies aim to improve how obesity and weight-related conditions are managed in everyday clinical practice.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.